Brentuximab vedotin

Niels W.C.J. van de Donk1,2,* and Eugen Dhimolea1

1Department of Medical Oncology; Dana Farber Cancer Institute; Harvard Medical School; Boston, MA USA; 2Department of Hematology; University Medical Center Utrecht; Utrecht, The Netherlands

Keywords: brentuximab vedotin, CD30, Hodgkin lymphoma, anaplastic large cell lymphoma, immunotherapy, monoclonal antibody

Brentuximab vedotin (SGN-35; Adcetris®) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Following binding to CD30, brentuximab vedotin is rapidly internalized and transported to lysosomes where MMAE is released and binds to tubulin, leading to cell cycle arrest and apoptosis.

Several trials have shown durable antitumor activity with a manageable safety profile in patients with relapsed/refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma or primary cutaneous CD30-positive lymphoproliferative disorders. Peripheral sensory neuropathy is a significant adverse event associated with brentuximab vedotin administration. Neuropathy symptoms are cumulative and dose-related. Multiple ongoing trials are currently evaluating brentuximab vedotin alone or in combination with other agents in relapsed/refractory patients, as well as patients with newly diagnosed disease.

Introduction

The successful application of immunotherapeutics in lymphoproliferative disorders, such as the anti-CD20 monoclonal antibodies (mAb) rituximab and ofatumumab, the anti-CD52 mAb alemtuzumab, and the radiolabelled antibodies 131I-tositumomab (Bexxar®) and 90Y-ibritumomab tiuxetan (Zevalin®) in non-Hodgkin lymphoma and chronic lymphocytic leukemia, has stimulated the development of mAbs for the treatment of other malignancies including Hodgkin lymphoma, systemic anaplastic large cell lymphoma or primary cutaneous CD30-positive lymphoproliferative disorders. Peripheral sensory neuropathy is a significant adverse event associated with brentuximab vedotin administration. Neuropathy symptoms are cumulative and dose-related. Multiple ongoing trials are currently evaluating brentuximab vedotin alone or in combination with other agents in relapsed/refractory patients, as well as patients with newly diagnosed disease.

CD30 is a 120 kDa transmembrane protein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. The protein encompasses six cysteine-rich pseudo-repeat motifs in its extracellular domain.1 The cytoplasmic domain of CD30 contains several binding sequences for members of the TNFR-associated factor (TRAF) family, which are implicated in the activation of NFκB, c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase pathways.2-4 CD30 is normally expressed in activated T cells, B cells and NK cells. CD30 expression has also been detected in several malignancies including Hodgkin lymphoma, anaplastic large cell lymphoma (ALCL), certain subtypes of B cell derived non-Hodgkin lymphomas, mature T cell lymphomas and germ-line malignancies. The restricted expression in these lymphocyte subsets renders it an attractive target for mAb therapy.

CD30 gene expression is regulated by several mechanisms, including Sp1 elements, microsatellite represor elements and histone deacetylases.5,6 In particular, in vitro administration of HDAC inhibitors induces downregulation of CD30 in Hodgkin lymphoma cell lines.6 CD30 can also be proteolytically cleaved and released as a soluble form (sCD30). High levels of sCD30 are associated with poor prognosis in patients with anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma.7,8 The ligand of CD30 (CD30L) is a transmembrane protein that belongs to the tumor necrosis factor receptor superfamily.1 CD30L is expressed in activated T cells, B cells, NK cells, eosinophils, neutrophils, monocytes and mast cells.

The function of CD30 and CD30L in human physiology remains unclear. No specific diseases or abnormalities have been linked to CD30 or CD30L mutations. The use of CD30-knockout animal models has produced inconclusive results with regard to the role of CD30 on removal of autoreactive T cells through apoptosis during development in the thymus (negative selection).9,10 However, CD30-mediated signaling is important for regulating the development of both effector and memory CD4-positive T cells.11 Various studies suggest that CD30L/CD30 signaling is linked to both Th1- and Th2-associated diseases.12-15 Inhibition of this pathway could prove beneficial in the treatment of autoimmune diseases.16,17 In vitro studies show contradictory results with CD30L/CD30L interaction either stimulating or inhibiting B cell proliferation and differentiation, but studies performed in mice suggest that CD30L/CD30 interactions promote secondary
In the case of refractory disease or relapse, ~50% of transplant-eligible patients can be cured by high-dose chemotherapy with autologous SCT, but survival following relapse after auto-SCT is very poor, with only 55% surviving at 2 y and 32% at 5 y. Non-transplant eligible patients with relapsed or refractory disease also have a poor outcome. Altogether, these data suggest that new targeted treatment strategies in this disease are still warranted, especially in the elderly and in patients with poor risk disease.

**Systemic anaplastic large cell lymphoma (ALCL).** Systemic ALCL accounts for approximately 10% of all T cell non-Hodgkin lymphomas and is characterized by large anaplastic lymphoid cells with uniform and strong CD30 expression (Fig. 2). The chromosome translocation t(2;5)(p23;q35) leads to the formation of the nucleophosmin-anaplastic lymphoma kinase (NPM1-ALK) fusion gene. The fusion protein contains a constitutively activated ALK kinase, which results in activation of multiple downstream pathways, including PI3K/AKT, Ras/ERK and JAK/Stat3, that leads to proliferation and protection against apoptosis. Other partner chromosomes have been identified that also result in ALK overexpression. Around 60% of systemic ALCL cases are ALK positive and these patients have significantly superior survival (5-y OS: 70%) when compared with ALK-negative patients (5-y OS: 49%). Treatment consists of CHOP-like chemotherapy with radiotherapy added in patients with limited-stage disease. Consolidation with high-dose therapy and auto-SCT should be considered in ALK-negative transplant eligible patients. Given the better prognosis in ALK-positive cases, auto-SCT is only considered in case of relapse or refractory disease. New treatment strategies are needed to improve cure rates of ALK-positive and especially ALK-negative ALCL patients.

**Primary cutaneous CD30-positive lymphoproliferative disorders.** The primary cutaneous CD30-positive lymphoproliferative disorders comprise approximately 25% of all cutaneous T cell lymphomas and include primary cutaneous ALCL (pcALCL) and lymphomatoid papulosis (LyP). Both diseases have a favorable prognosis, but differ with regard to their clinical presentation. LyP is characterized by recurrent papulonodular lesions
that undergo spontaneous regression after weeks or months. In pcALCL, there are solitary or grouped, rapidly growing large tumors or thick plaques, but sometimes it presents with multifocal lesions. Generalized LyP can be treated with UV-light phototherapy, topical steroids or low-dose methotrexate, whereas localized pcALCL is treated with surgical excision or radiotherapy. Chemotherapy is often given for multifocal pcALCL. However, patients with these tumors tend to develop new lesions after therapy is stopped.

**Brentuximab Vedotin**

**Antibody generation and mechanisms of action.** Brentuximab vedotin is generated by conjugating the mouse-human chimeric IgG1 anti-CD30 mAb (cAC10; SGN-30), to the synthetic dolastatin 10 analog monomethylauristatin A (MMAE), via a protease-sensitive dipeptide linker. Each mAb molecule carries an average of 4 MMAE groups. Brentuximab vedotin binds to the CD30 receptor and is internalized via endocytosis. Upon exposure to proteolytic lysosomal enzymes, MMAE molecules are released in the intracellular space. Binding of MMAE to tubulin disrupts the microtubule network within the cell, leading to induction of G2/M-phase cell cycle arrest and apoptosis. The advantage of the citrulline-valine linker is that it is highly stable in plasma, whereas the dipeptide linker is rapidly and efficiently cleaved by lysosomal enzymes after internalization in antigen-positive cells. This results in lower in vivo toxicity and higher efficacy when compared with conjugates with lower stability in plasma. Brentuximab vedotin may also be mediated by antibody-dependent cellular phagocytosis (ADCP) or via direct effects on tumor cell signaling, both of which are mechanisms of action of SGN-30. In addition, a small fraction of free MMAE diffuses out of the targeted CD30-positive cells, allowing it to kill surrounding cells in the tumor microenvironment which can support tumor growth by production of growth factors and via adhesion.

**Preclinical evaluation of brentuximab vedotin.** Brentuximab vedotin induced cell death of CD30-positive tumor cells in vitro including Hodgkin lymphoma cells, cutaneous T cell lymphoma and anaplastic large cell lymphoma cells, with IC50 < 10 ng/ml, but was more than 300-fold less active on CD30-negative cells. In addition, brentuximab vedotin had antitumor activity in xenograft models of Hodgkin lymphoma and anaplastic large cell lymphoma. In the Hodgkin lymphoma xenograft model, improved antitumor activity was observed when brentuximab vedotin was administered with chemotherapeutic agents, including gemcitabine and the combination of adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).

**Antibody pharmacokinetics.** Increases in exposure to the antibody-drug conjugate and free MMAE are approximately proportional to dose when brentuximab vedotin is administered every 3 weeks. Half-life estimates for the antibody-drug conjugate and for free MMAE are 4–6 d and 3–4 d, respectively. When brentuximab vedotin was administered in a weekly schedule, increases in both brentuximab vedotin and free MMAE exposures were approximately dose-proportional. Peak brentuximab vedotin blood concentrations were achieved at the end of the infusion in both dosing regimens, whereas peak free MMAE concentrations occurred within 1 to 3 d following each infusion.

**Clinical development of brentuximab vedotin.**

1. **Hodgkin lymphoma.**

**Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma.** Two unconjugated anti-CD30 antibodies, SGN-30 and MDX-060, had limited clinical activity in Hodgkin lymphoma. Brentuximab vedotin, however, showed high anti-tumor activity accompanied with limited toxicity in a recently published Phase 1 study (NCT00430846). In this study, 42 (93%) out of the 45 patients who were treated had relapsed/refractory classical Hodgkin lymphoma, while 2 patients had systemic ALCL and 1 had CD30-angioimmunoblastic T cell lymphoma (Table 1). They had received a median of 3 preceding lines of chemotherapy, including auto-SCT in 73% of the patients. Brentuximab vedotin was administered at doses of 0.1 to 3.6 mg/kg every 3 weeks; premedication was not required. Study treatment was stopped upon disease progression. A dose of 1.8 mg/kg administered every 3 weeks was considered the highest dose without unacceptable adverse effects. The most common adverse events, predominantly of grade 1 and 2, were fatigue (36%), pyrexia.
arthralgia and pyrexia. In addition, peripheral sensory neuropathy was observed in 66% of patients (predominantly grade 1 or 2). Only 6 patients (14%) experienced grade 3 peripheral sensory neuropathy. In addition, 4 patients (9%) experienced peripheral motor neuropathy, including 3 cases with grade 3. Eight patients discontinued treatment because of neuropathy. Grade 1/2 acute infusion reactions occurred in 14% of patients but routine premedications were not required. Both patients who developed anti-brentuximab antibodies experienced infusion reactions. At least PR was achieved in 59% of patients with a CR rate of 34%. Median time to objective response was 8.1 weeks. Stable disease was achieved in an additional 32% of patients. Six out of the 7 patients with B-symptoms had resolution of these symptoms. At least PR was achieved in 54% (CR in 29%) of the Hodgkin lymphoma patients and in 4 out of 5 patients with ALCL (all CR). The patient with peripheral T cell lymphoma (PTCL-NOS) achieved a PR. The remissions were durable with median duration of response not yet reached at a median follow-up of 45 weeks on study. Median PFS was 29 weeks and median OS was not reached. Treatment was accompanied with reductions of cytokine and chemokine concentrations.

Based on the encouraging results of these Phase 1 studies, a Phase 2 study (NCT00848926) was initiated in which patients with relapsed/refractory classical Hodgkin lymphoma were treated with brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles (Table 1). Preliminary data of 102 patients demonstrate an objective response rate (PR + CR) of 75%, with 34% CR. The median duration of response not yet reached after a median follow-up of 45 weeks. For the whole group, the median duration of response was at least 9.7 mo. Stable disease was achieved in an additional 32% of patients. Six out of the 7 patients with B-symptoms had resolution of these symptoms. At least PR was achieved in 54% (CR in 29%) of the Hodgkin lymphoma patients and in 4 out of 5 patients with ALCL (all CR). The patient with peripheral T cell lymphoma (PTCL-NOS) achieved a PR. The remissions were durable with median duration of response not yet reached at a median follow-up of 45 weeks on study. Median PFS was 29 weeks and median OS was not reached. Treatment was accompanied with reductions of cytokine and chemokine concentrations.

Another study (NCT00051597) evaluated brentuximab vedotin in a more frequent (once weekly) dosing schedule in patients with relapsed/refractory CD30-positive malignancies (Table 1). This Phase 1 study enrolled 38 Hodgkin lymphoma patients, 5 patients with systemic ALCL, and 1 with a peripheral T cell lymphoma. Patients had received a median of 3 prior chemotherapy regimens and 68% had undergone prior auto-SCT. Brentuximab vedotin MTD was defined as 1.2 mg/kg. The most common side effects were again fatigue, nausea, diarrhea, arthralgia and pyrexia. In addition, peripheral sensory neuropathy was observed in 66% of patients (predominantly grade 1 or 2). Only 6 patients (14%) experienced grade 3 peripheral sensory neuropathy. In addition, 4 patients (9%) experienced peripheral motor neuropathy, including 3 cases with grade 3. Eight patients discontinued treatment because of neuropathy. Grade 1/2 acute infusion reactions occurred in 14% of patients but routine premedications were not required. Both patients who developed anti-brentuximab antibodies experienced infusion reactions. At least PR was achieved in 59% of patients with a CR rate of 34%. Median time to objective response was 8.1 weeks. Stable disease was achieved in an additional 32% of patients. Six out of the 7 patients with B-symptoms had resolution of these symptoms. At least PR was achieved in 54% (CR in 29%) of the Hodgkin lymphoma patients and in 4 out of 5 patients with ALCL (all CR). The patient with peripheral T cell lymphoma (PTCL-NOS) achieved a PR. The remissions were durable with median duration of response not yet reached at a median follow-up of 45 weeks on study. Median PFS was 29 weeks and median OS was not reached. Treatment was accompanied with reductions of cytokine and chemokine concentrations.

Based on the encouraging results of these Phase 1 studies, a Phase 2 study (NCT00051597) was initiated in which patients with relapsed/refractory classical Hodgkin lymphoma were treated with brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles (Table 1). Preliminary data of 102 patients demonstrate an objective response rate (PR + CR) of 75%, with 34% CR. The median duration of CR was not yet reached. The most common treatment-related adverse events were sensory peripheral neuropathy, nausea, fatigue, neutropenia and diarrhea.
Thus, the available data shows that single agent brentuximab vedotin induces responses in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma, and has acceptable toxicity. More frequent administration with the once weekly schedule may be useful for short-term remission induction strategy in patients with bulky or symptomatic disease requiring rapid tumor debulking. However, the weekly dosing regimen was accompanied with a significantly higher rate of peripheral neuropathy compared with every 3-week dosing, indicating that, when a response is achieved, a less frequent dosing regimen can be initiated for consolidation and to minimize toxicity.

**Brentuximab vedotin before or after auto-SCT.** Several Phase 2 studies have been initiated to test single agent brentuximab vedotin as salvage therapy preceding auto-SCT in patients with relapsed/refractory Hodgkin lymphoma (NCT01393717; NCT01508312). Furthermore, a randomized, multicenter Phase 3 trial is currently enrolling patients with classical Hodgkin lymphoma who underwent auto-SCT for relapse or refractory disease (NCT01100502). This study will compare the efficacy and safety of brentuximab vedotin to placebo treatment in patients at high-risk of residual disease post-transplant.

**Allogeneic transplant following brentuximab vedotin.** Hodgkin lymphoma patients with relapse following auto-SCT have a very poor prognosis. Allo-SCT is a potentially curative procedure for these patients, but the lack of sufficient pre-transplant disease control limits the applicability of this approach. A retrospective analysis and a subgroup analysis of patients participating in two Phase 2 studies examined the efficacy and toxicity of allo-SCT following induction of remission with brentuximab vedotin. This approach resulted in prolonged disease control, without delay in engraftment or increase in acute graft-vs-host disease, chronic graft-vs-host disease or non-relapse mortality.

**Brentuximab vedotin in newly diagnosed Hodgkin lymphoma.** Based on the efficacy of single agent brentuximab vedotin in relapsed/refractory disease and in vitro data showing synergy between brentuximab vedotin and chemotherapy, several studies are testing the efficacy and safety of combination treatments in newly diagnosed patients.

An ongoing, but not recruiting, Phase 1 study (NCT01060904) is evaluating the safety of brentuximab vedotin (0.6, 0.9 or 1.2 mg/kg; on days 1 and 15 of each 28-day cycle in combination with ABVD or AVD; up to 6 cycles MTD, not reached). Hodgkin’s lymphoma (NCT01393717). Treatment was given as a single agent or in combination with chemotherapy. The median duration of response was 13 mo. Median PFS was 14.6 mo and median OS was not yet reached. Importantly, median PFS with brentuximab vedotin was significantly longer than the median PFS achieved with the most recent prior therapy. After discontinuing treatment, 16 patients received a transplant (allo-SCT in 8 and auto-SCT in 8). Peripheral sensory neuropathy was observed well tolerated with no dose-limiting toxicities observed up to 1.2 mg/kg. The most common adverse events were nausea (77%), neutropenia (77%), peripheral sensory neuropathy (48%) and fatigue (45%). However, 40% of the patients treated with brentuximab vedotin and ABVD had pulmonary toxicity occurring during cycles 3–6, which is higher when compared with ABVD alone. Thus far, no patients in the AVD cohort experienced a pulmonary toxicity event indicating that brentuximab vedotin should not be combined with bleomycin (Younes A, personal communication, March 2012). All 10 patients who had a response assessment available after completion of frontline therapy had achieved CR (Table 2). Based on these data a Phase 3 trial is planned to assess frontline treatment with brentuximab vedotin plus AVD as compared with ABVD without brentuximab vedotin (Younes A, personal communication, March 2012).

The aim of another ongoing Phase 2 study is to compare the activity of brentuximab vedotin combined with AVD (doxorubicin, vindesine and dacarbazine) in older patients (>60 y) with previously untreated stage II-IV classical Hodgkin lymphoma (NCT01476410).

**2. Systemic anaplastic large cell lymphoma.** Younes et al. treated 2 patients with relapsed/refractory systemic ALCL with brentuximab vedotin once every 3 weeks. Both patients achieved a CR with a duration of 17 and 5 mo.

In the Phase 1 study (NCT00051597) reported by Fanale et al. systemic ALCL patients with relapsed or refractory disease were treated with brentuximab vedotin. The weekly dosing schedule resulted in CR in 4 out of 5 patients, while the other patient who was treated at the lowest dose had stable disease. In contrast, unconjugated anti-CD30 antibodies had only modest clinical activity in systemic ALCL.

Based on these promising results, a Phase 2 study (NCT00866047) was initiated in which brentuximab vedotin was administered at a dose of 1.8 mg/kg every 3 weeks to 58 patients with relapsed/refractory systemic ALCL (Table 1). At least PR was achieved in 86% of patients, including CR in 53% patients. Patients with ALK-positive and ALK-negative disease had similar response rates. Notably, patients who never responded to previous therapy achieved a response to brentuximab vedotin (n = 13; ≥PR: 77%; CR: 31%). The median duration of the response was 13 mo. Median PFS was 14.6 mo and median OS was not yet reached. Importantly, median PFS with brentuximab vedotin was significantly longer than the median PFS achieved with the most recent prior therapy. After discontinuing treatment, 16 patients received a transplant (allo-SCT in 8 and auto-SCT in 8). Peripheral sensory neuropathy was observed.
in 41% of patients, including 17% with a grade 3 neuropathy. Again, the majority (79%) of these patients experienced resolution or improvement of neuropathy.

Several reports indicate that retreatment with brentuximab vedotin is possible after previous response or stabilization of disease following brentuximab vedotin therapy.\(^{44,45}\) An ongoing Phase 2 retreatment study is enrolling patients who previously experienced an objective response to brentuximab vedotin (NCT00947856).

These data suggest that durable remissions can be achieved with brentuximab vedotin in patients with relapsed/refractory systemic ALCL. Based on these results, a Phase 1 study is now evaluating brentuximab vedotin administered in sequence and in combination with multiagent chemotherapy as first line treatment in systemic ALCL (NCT01309789).

3. Primary cutaneous CD30-positive lymphoproliferative disorders. A Phase 2 study (NCT00099255) evaluated the safety and efficacy of single agent SGN-30 in patients with pcALCL and LyP or CD30-positive large cell transformation of mycosis fungoides who had failed to respond to local radiation therapy or systemic therapy.\(^{46}\) The overall response rate in 23 evaluable patients was 70% with an acceptable toxicity profile. A Phase 2 study is currently enrolling patients with these skin lymphomas to test efficacy and toxicity profile of brentuximab vedotin (NCT01352520).

**Future Perspectives**

Although the majority of patients with Hodgkin lymphoma can be cured with frontline therapy, new agents are needed, particularly for elderly patients, relapsed/refractory patients ineligible for auto-SCT, patients with refractory disease after salvage chemotherapy, and patients who relapse after auto-SCT. Brentuximab vedotin is a promising novel cancer treatment and it has shown significant single-agent antitumor activity in heavily pretreated patients with acceptable toxicity. Various ongoing trials are currently evaluating brentuximab vedotin alone and in combination with other agents as frontline therapy or salvage therapy, including induction therapy preceding auto-SCT. In the front-line setting, the aim is to reduce toxicity in patients with very favorable disease and to improve outcomes in patients with high risk for relapse. In addition, the feasibility of using brentuximab vedotin as maintenance therapy after auto-SCT is under evaluation. These studies will provide important data with regard to the optimal regimens that incorporate brentuximab vedotin for the treatment of Hodgkin lymphoma. Several other promising novel agents that target the tumor cell or the microenvironment such as mTOR inhibitors, lenalidomide and rituximab are currently under investigation in Hodgkin lymphoma as single agent or in combination with other therapies.\(^{47-49}\)

Despite the relative efficacy of chemotherapy in systemic ALCL, novel agents are still needed for relapsed or refractory patients. Recent clinical trials in systemic ALCL showed clinical activity of brentuximab vedotin in heavily pretreated patients in both ALK-positive and -negative tumors. Ongoing studies are investigating the value of brentuximab vedotin in patients with newly diagnosed disease. Other promising novel agents for the treatment of systemic ALCL include inhibitors of the NPM1-ALK fusion protein in ALK-positive cases, histone deacetylase inhibitors, pralatrexate (a folate analog) and other mAbs such as the anti-CD25 daclizumab or anti-CD4 zanolimunab.\(^{50-54}\)

Most studies focused on the treatment of Hodgkin lymphoma and ALCL. However, studies currently enrolling patients are also evaluating brentuximab vedotin in other tumors with variable CD30 expression such as mycosis fungoides, Sezary syndrome, acute lymphoblastic leukemia, acute myeloid leukemia, multiple myeloma, chronic lymphatic leukemia and NK-cell neoplasms.

One of the clinically most important adverse events related to brentuximab vedotin treatment is the cumulative, dose-related peripheral neuropathy, which is predominantly sensory. The development of neuropathy is a consequence of the microtubule assembly inhibition by the cytotoxic component of brentuximab vedotin (MMAE). Dose adjustments, delays or lengthening of dose interval should be considered to manage neuropathy and to enable continuation of treatment.\(^{55}\) Grade 3 and 4 neuropenia must also be managed by dose delays or reductions. Support with growth factors can also be considered for subsequent cycles of therapy. Importantly, in January 2012 Seattle Genetics announced that progressive multifocal leukoencephalopathy may be associated with the use of brentuximab vedotin. In addition, a contraindication warning against concomitant use of bleomycin and brentuximab vedotin was given because of increased risk of pulmonary toxicity. Serious pulmonary toxicity was also observed when SGN-30 was combined with gemcitabine, vinorelbine and pegylated liposomal doxorubicin (GVD).\(^{56}\) This observation indicates that interactions between SGN-30 or brentuximab vedotin with certain agents such as gemcitabine and bleomycin, may potentially lead to development of pneumonitis.

An important challenge will be the identification of patient subsets that will benefit most from brentuximab vedotin-based therapeutics. Biomarker assessment in future studies will help to evaluate the risk/benefit profile and tailor individualized therapeutic approaches.

Also other CD30 targeting agents are currently in clinical testing either as single agent or in combination with other drugs in Hodgkin lymphoma and ALCL. These include the human IgG1 monoclonal antibody MDX-060,\(^{36}\) and its derivative MDX-1401, which has a nonfucosylated Fc region leading to higher affinity to Fcγ receptors and improved ADCC;\(^{57}\) the humanized monoclonal antibody XmAb2513,\(^{38}\) which has an Fc region engineered to have increased binding affinity to Fcγ receptors leading to improved Fcγ receptor-dependent effector functions; and AFM13 which is a recombinant antibody construct targeting both CD30 and CD16a, which is present on the surface of NK cells, macrophages and neutrophils (NCT01221571).

In summary, brentuximab vedotin offers an important new therapeutic option for patients with heavily pretreated relapsed/refractory Hodgkin lymphoma, systemic ALCL and primary cutaneous CD30-positive lymphoproliferative disorders. Future research will be directed at developing combinations with brentuximab vedotin for patients with relapsed or newly diagnosed disease.
References

1. Smith CA, Gruss HJ, Davis T, Anderson D, Farzad T, Baker E, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNE Cell 1993; 73:1549-60; PMID:8391931; http://dx.doi.org/10.1016/0092-8674(93)90306-I.

2. Duckett CS, Gedrich RW, Gillilan MC, Thompson CB. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 1997; 17:5155-42; PMID:9302281.

3. Ansieau S, Schreffl kin, Motsalou G, Brand H, Duyster J, Kaye K, et al. Tumor necrosis factor receptor-associated factor (TRAF1)-1, TRAF-2 and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factorkappa B activation. Proc Natl Acad Sci USA 1996; 93:14053-8; PMID:8849367; http://dx.doi.org/10.1073/pnas.93.24.14053.

4. Harlin H, Podack E, Boothby M, Alegre ML. TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/ protein-10 mitogen-activated protein kinase-dependent mechanism. J Immunol 2002; 169:2451-9; PMID:12193714.

5. Croazer EJ, Gour AM, Abraham LJ. Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. Am J Pathol 2000; 157:1709-31; PMID:11079083; http://dx.doi.org/10.1016/s0002-9440(00)90543-2.

6. Buglio M, Mammidipudi V, Khadkhe KM, Brady H, Heise C, Besterman J, et al. The class-1 HDAC inhibitor MGC000105 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Br J Haematol 2010; 151:387-96; PMID:20880107; http://dx.doi.org/10.1111/j.1365-2141.2010.07542.x.

7. Pizzolo G, Vinante F, Chisoli M, Dallenbach F, Josimovics-Alasevic O, Diamantstein T, et al. Serum levels of soluble CD30 molecule (Kre-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br J Haematol 1990; 75:282-4; PMID:2164839; http://dx.doi.org/10.1111/j.1365-2141.1990.tb02664.x.

8. Sjoberg J, Halthur C, Kristinsson SY, Landgren O, Nygell UA, Dickman PW, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2003. Blood 2012; 119:990-8; PMID:22417892; http://dx.doi.org/10.1182/blood-2011-08-302604.

9. Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 2008; 112:2977-83; PMID:18096762; http://dx.doi.org/10.1182/blood-2007-10-115493.

10. Everse AM, Helenowski I, Ramulade E, Nahban C, Karmali R, Hanson B, et al. A retrospective multivariate analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 2012; 119:692-5; PMID:2217038; http://dx.doi.org/10.1182/blood-2011-09-378414.

11. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin Disease. N Engl J Med 1998; 339:1506-14; PMID:9814499; http://dx.doi.org/10.1056/NEJM199811263392203.

12. Sureda A, Constans M, Iriodro A, Arranz R, Caballero MD, Vidal MJ, et al.; Grupo Español de Linfomas/ Grupo Español de Linfomas/SEMLymphoma. International Peripheral T-Cell Lymphoma Project. ALK-negative peripheral T-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphomas, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111:1546-54; PMID:18385450; http://dx.doi.org/10.1182/blood-2008-01-134270.

Acknowledgments

The authors thank Dr. Roos Leguit (Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands) for providing images for Figures 1 and 2.

N.W.vdD. received research funding from and contracted research for Celgene. E.D. did not receive funding.

Financial Disclosure

mAbs Volume 4 Issue 4

2013 Landes Bioscience. Do not distribute.
37. Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009; 146:171-9; PMID:19469695; http://dx.doi.org/10.1111/j.1365-2141.2009.07740.x.

38. Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008; 111:1848-54; PMID:18079362; http://dx.doi.org/10.1182/blood-2007-09-093917.

39. Chen RW, Forman SJ, Palmer J, Tsi NC, Poplewell L, Delioukina ML, et al. Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma. ASH Annual Meeting Abstracts 2011; 118:664.

40. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). J Clin Oncol 2011; 29:8062.

41. Dave M, Reddy SA, Pinter-Brown L, Korman NJ, Zie J, Kennedy DA, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 2009; 15:6217-24; PMID:19789316; http://dx.doi.org/10.1158/1078-0432.CCR-09-0162.

42. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85:320-4; PMID:20229590.

43. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011; 118:5119-25; PMID:21355090; http://dx.doi.org/10.1182/blood-2011-07-362475.

44. Blum KA. Upcoming diagnostic and therapeutic developments in classical Hodgkin’s lymphoma. Hematology Am Soc Hematol Educ Program 2010; 2010:93-100; PMID:21239777; http://dx.doi.org/10.1182/ash.aeshed-2010.1.93.

45. Merkel O, Hamacher F, Siff E, Kenner L, Greil R, European Research Initiative on Anaplastic Large Cell Lymphoma. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunotherapeutic tools. Mol Cancer Ther 2011; 10:1127-36; PMID:21712478; http://dx.doi.org/10.1158/1535-7163.MCT-11-0042.

46. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011; 117:5827-34; PMID:21555097; http://dx.doi.org/10.1182/blood-2010-10-312603.

47. d’Amore F, Radford J, Kelerand T, Jerkeman M, Tilly H, Osterborg A, et al. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 2010; 150:565-73; PMID:20629661; http://dx.doi.org/10.1111/j.1365-2141.2010.08298.x.

48. O’Connor OA, Horwitz S, Hampl P, Portlock C, Moskowitz CH, Sarasohn D, et al. Phase II-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009; 27:4357-64; PMID:19652067; http://dx.doi.org/10.1200/JCO.2008.20.8470.

49. Lindén O. Remission of a refractory, anaplastic large-cell lymphoma after treatment with dacarbazine. N Engl J Med 2004; 351:1466-7; PMID:15459315; http://dx.doi.org/10.1056/NEJM200409303510412.

50. Forero-Torres A, Berryman RB, Bartlett NL, Chen RW, Fanale MA, et al. Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL). ASH Annual Meeting Abstracts 2011; 118:3711.

51. Blum KA, Jung SH, Johnson JL, Lin TS, Hsi ED, Lucas DM, et al.; Cancer and Leukemia Group B. Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine and liposomal doxorubicin is associated with an FcγRIIA-158 V/F polymorphism. Ann Oncol 2010; 21:2246-54; PMID:20423913; http://dx.doi.org/10.1093/annonc/mdq211.

52. Cardarelli PM, Moldovan-Loomis MC, Preston B, Black A, Pasmore D, Chen TH, et al. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Clin Cancer Res 2009; 15:3376-83; PMID:19401346; http://dx.doi.org/10.1158/1078-0432.CCR-08-3222.

53. Blum KA, Smith M, Fueng H, Zalevsky J, Combs D, Ramesy DA, et al. Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients. Safety, pharmacokinetics (PK), immunogenicity and efficacy. J Clin Oncol 2009; 27:8533.